The global Radiation, Detection, Monitoring & Safety Market, valued at US$3,132.2million in 2023, is forecasted to grow at a ...

About PYRUKYND® (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

May 14, 2025) - Tower Resources Ltd. (TSXV: TWR) (" Tower " or the " Company ") announces it has initiated the spring 2025 diamond drill program to test the high-grade Blue Sky, Thunder and Thunder ...